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Palliative systemic treatment  
of patients with pancreatic cancer 
— should reimbursement  
of nab-paclitaxel change the current 
management paradigm?
ABSTRACT
Pancreatic cancer is associated with poor prognosis. In the majority of patients the disease is diagnosed at an 
inoperable stage, so palliative chemotherapy is the only possible management. In a highly clinically and biochemi-
cally selected subpopulation two chemotherapy multi-drug schemes: FOLFIRINOX regimen and combination of 
nab-paclitaxel with gemcitabine, are more effective than gemcitabine alone, being the current standard of treat-
ment. As there is a lack of direct comparison between doublet and triplet chemotherapies and the prognosis of 
patients enrolled to ACCORD 11 and MPACT clinical trials is similar, an attempt at indirect analysis was undertaken. 
It seems that chemotherapy with the use of FOLFIRINOX regimen prolongs overall survival significantly more and 
mainly has a beneficial impact on quality of life. In the authors’ opinion, the possibilities of using chemotherapy 
containing nab-paclitaxel and gemcitabine are quite limited. In patients with worse performance status monotherapy 
with gemcitabine or best supportive care should remain a standard of management.
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Introduction
Pancreatic cancer is a malignant neoplasm of ex-
tremely poor prognosis as compared with other — more 
prevalent — malignancies. The number of reported new 
cases in Poland is about 3500 annually, which accounts 
for 2.2% of total cancer incidence. The number of deaths 
is estimated to be approximately 4700 (5% of deaths due 
to cancer diseases) [1].
The diagnosis of pancreatic adenocarcinoma is usu-
ally late due to long asymptomatic or minimally symp-
tomatic course of disease. Consequently, in majority of 
patients systemic cytotoxic treatment is the only thera-
peutic option that is able to influence prognosis. Postop-
erative chemotherapy is indicated for all patients after 
surgical procedure, both microscopically radical and 
non-radical (R1). However, this management applies to 
less than 20% of patients with diagnosis of pancreatic 
cancer. In 30–40% of patients, pancreatic malignancy 
is diagnosed as locally advanced disease, when surgical 
treatment is impossible. In some patients the resect-
ability could be reassessed after systemic treatment (the 
role of preoperative irradiation is still unclear), however 
the rest of patients receive only palliative chemotherapy. 
In 40–50% of patients, pancreatic cancer is diagnosed 
at an the metastatic stage and systemic treatment is the 
only therapeutic modality.
Palliative systemic treatment in patients with pan-
creatic cancer is discussed in the following sections of 
the presented article.
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Palliative chemotherapy in patients 
with pancreatic cancer
In 1997 the results of a clinical trial that compared 
efficacy of palliative gemcitabine chemotherapy with 
fluorouracil-based systemic treatment in patients with 
advanced pancreatic cancer were published. They in-
dicated higher activity of the first one cytotoxic drug. 
Median overall survival (mOS) in patients treated with 
gemcitabine reached 5.6 months, however in fluorouracil 
arm it was 4.4 months (p = 0.0025). Despite small (5.4%) 
objective response rate (ORR), chemotherapy with 
gemcitabine contributed to better pain control in up to 
a quarter of patients. The treatment was well tolerated; 
haematological toxicity was mainly observed [2]. Over the 
next few years gemcitabine monotherapy was the only 
standard option of palliative treatment. This therapy is 
still a valuable choice in patients with worse performance 
status (ECOG 2), with moderately increased serum 
bilirubin concentration, e.g. > 1.5 upper limit of normal 
(ULN), with significant concomitant diseases, or in pa-
tients unwilling to accept the risk of toxicity.
A combination of gemcitabine with a second cyto-
toxic drug (e.g. cisplatin, capecitabine) did not influence 
OS despite observed increase in the median progres-
sion-free survival (mPFS) and ORR, but it was associ-
ated with intensified toxicity [3, 4]. Some retrospective 
analyses suggest that platinum-based chemotherapy 
results in a greater advantage in patients with mutations 
in BRCA1or BRCA2 genes [5].
Between 2007 and 2013 the results of 3 phase III 
clinical trials were published, that indicated the OS 
benefits from multi-drug chemotherapy in patients with 
advanced pancreatic cancer as compared to single-agent 
gemcitabine — the standard option at that time. 
In the first study gemcitabine was combined with er-
lotinib in 569 patients with unresectable, locally advanced 
or metastatic pancreatic cancer. A small but statistically 
significant difference in OS was noticed in favour of patients 
treated with erlotinib and gemcitabine; median OS was 
increased by 2 weeks (6.24 vs. 5.91 months, HR 0.82; 95% 
Cl: 0.69–0.99; p = 0.038); median PFS was also increased 
(3.75 vs. 3.55 months, HR 0.77; 95% Cl: 0.64–0.92; p = 0.004). 
However, objective response rates (8.6% vs. 8%) as well 
as disease control rates (57.5% vs. 49.2%; p = 0.07) were 
comparable in both treatment arms. Combined therapy was 
associated with increased toxicity. Rash, diarrhoea, infections 
and stomatitis were more frequently observed, but they didn’t 
influence the quality of life (QoL) of treated patients [6].
In a second — French academic study (PRODIGE 
4), the efficacy of multi-drug chemotherapy with the 
FOLFIRINOX regimen was assessed in 342 patients 
with metastatic pancreatic cancer. Median OS was in-
creased by more than 4 months (11.1 vs. 6.8 months) and 
relative risk of death was decreased by 43% (HR 0.57; 
95% Cl: 0.45–0.73; p < 0.001). The beneficial effects 
were also observed for PFS (median: 6.4 vs. 3.3 months; 
HR 0.47; 95% Cl: 0.37–0.59; p < 0.001) and ORR (32% 
vs. 9%; p < 0.001) [7].
In the third MPACT study, conducted in the largest 
population (861 patients), gemcitabine was combined 
with nab-paclitaxel (nanoparticle complexes of paclitaxel 
with albumin). As compared to gemcitabine monother-
apy, the median OS was increased by nearly 2 months 
(8.5 vs. 6.7 months) and risk of death was decreased by 
28% (HR 0.72; 95% Cl: 0.62–0.83; p < 0.001). mPFS 
was also increased (5.5 vs. 3.7 months respectively, HR 
0.69; 95% Cl: 0.58–0.82; p < 0.001), similarly ORR (23% 
vs. 7%; p < 0.001) [8].
FOLFIRINOX regimen
Patients included in the study
The ACCORD 11 (PRODIGE 4) study enrolled 
patients with stage IV pancreatic cancer, not older than 
75 years, with performance status of 0–1 according to 
ECOG (Eastern Cooperative Oncology Group) score. 
Exclusion criteria, among others, included serum bili-
rubin concentration higher than 1.5 x ULN and creati-
nine concentration equal to or higher than 120 µmol/L 
(1.36 mg/dL).
Adverse reactions and quality of life
Multi-drug chemotherapy was associated with higher 
G3–G4 toxicity — more frequently observed reactions 
included neutropenia (46% vs. 21%; p < 0.001), febrile 
neutropenia (5% vs. 1%; p = 0.03), thrombocytopenia 
(9% vs. 4%; p = 0.04), diarrhoea (13% vs. 2%; p < 0.001) 
and sensitive neuropathy (9% vs. 0%; p < 0.001).
According to the study protocol, routine primary 
prophylaxis of febrile neutropenia with filgrastim was 
not allowed, except for the patients with other important 
factors that increase the risk of febrile neutropenia. Ad-
ditionally, in patients with neutropenia of at least grade 
2 during multi-drug chemotherapy, it was recommended 
to continue the chemotherapy in a reduced dose (after 
recovery of neutrophil count to normal range). How-
ever, G-CSF was used in 43% of patients that received 
multi-drug regimen, compared to 5% of patients treated 
with gemcitabine alone. Although higher toxicity, 
chemotherapy according to the FOLIRINOX regimen 
had a positive impact on QoL, by decreasing relative risk 
of its deterioration by 63% (HR 0.47; 95% Cl: 0.3–0.7; 
p < 0.001); after 6 months, significant deterioration 
of QoL was detected in 66% of patients who received 
gemcitabine alone vs. 31% in those who were treated 
by the multi-drug regimen [7]. Table 1 summarises 
the recommendations of the study authors and ASCO 
(American Society of Clinical Oncology) experts regard-
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ing management of toxicities related to FOLFIRINOX 
chemotherapy [7, 9]. Of note, whilst primary prophylaxis 
of febrile neutropenia is not recommended, modifica-
tion of the doses of cytotoxic drugs should be primarily 
considered in case of neutropenia. 
Gemcitabine with nab-paclitaxel
Patients included in the study
The MPACT study, that assessed the combination of 
gemcitabine with nab-paclitaxel compared to gemcitabine 
alone, enrolled patients without age limitation (however, 
patients aged over 75 years accounted for only 10% of 
the study population), with a performance status of at 
least 70 according to the Karnofsky Performance Scale 
(KPS) (KPS 70 was found in 7% of patients only). The 
biochemical criterion regarding the permissible bilirubin 
level was more stringent than in the ACCORD11 study 
— patients with level higher than ULN were excluded 
from the trial. The creatinine level was required to be 
within normal range or the calculated value of creatinine 
clearance should amount to at least 60 mL/min/1.73 m2.
Adverse reactions and quality of life
The clinical benefit from doublet chemotherapy 
was counterbalanced by its higher toxicity. More 
frequently observed adverse reactions (grade 3/4) in-
cluded: leukopenia (31% vs. 16%), neutropenia (38% 
vs. 27%), fatigue (17% vs. 7%), peripheral neuropathy 
(17% vs. 1%), sepsis (5% vs. 2%) and pneumonia (4% 
vs. 1%). The risk of febrile neutropenia was 3% vs. 1%, 
respectively; GCS-F was administered in 26% vs. 15% 
of patients, respectively. In the MPACT study QoL was 
not assessed [8].
Table 2 summarises the recommendations of man-
agement of treatment-related toxicity that were made 
by study authors and ASCO experts.
What to choose: FOLFIRINOX  
or nab-paclitaxel with gemcitabine?
One of the criteria of the Ministry of Health (MoH) 
drug program of treatment of pancreatic cancer, re-
cently initiated in Poland, indicates that combination of 
nab-paclitaxel and gemcitabine could be used entirely 
in patients ineligible for chemotherapy according the 
FOLFIRINOX regimen. Why such a provision was 
implemented, and which group of patients could be 
affected in practice?
There was no clinical study that directly compared 
the results of FOLFIRINOX-based treatment with 
a combination of nab-paclitaxel and gemcitabine, so 
an attempt to indirectly compare those data is war-
ranted.
Table 1. Recommendations of study authors and ASCO experts regarding management of toxicities resulting from 
FOLFIRINOX chemotherapy 
Adverse events Recommendations of study authors ASCO recommendations
Neutropenia/FN Decrease irinotecan dose (150 mg/m2) and give 
up injections of FU and folinic acid, then decrease 
oxaliplatin dose (65 mg/m2)
Give up injections of FU and infusion 
of folinic acid + additionally decrease 
oxaliplatin and irinotecan dose by 20%
Thrombocytopenia Decrease oxaliplatin dose (60 mg/m2), decrease FU 
dose (injection and infusion by 25%), then decrease 
irinotecan dose (150 mg/m2)
Diarrhoea Decrease irinotecan dose (150 mg/m2) and give up 
injections of FU and folinic acid
Decrease irinotecan and FU dose 
Mucositis/”hand–foot” syndrome Decrease FU dose (injection and infusion, by 25%)
Neuropathy Decrease oxaliplatin dose Decrease oxaliplatin dose 
Hyperbilirubinemia Decrease dose or give up irinotecan and/or decrease 
oxaliplatin and/or FU dose
Nausea or vomiting Decrease irinotecan dose (150 mg/m2) or decrease 
oxaliplatin dose (60 mg/m2), or decrease FU dose 
(injection and infusion, by 25%)
Give up injections of FU and infusion 
of folinic acid + additionally decrease 
oxaliplatin and irinotecan dose by 20%
Primary prophylaxis of FN Not recommended Not recommended
Secondary prophylaxis of FN Consider after FN episode or in case of recurrent 
neutropaenia grade 3 or 4, despite dose reduction 
Dose modifications; G-CSF is not 
recommended
FN — febrile neutropenia; FU — fluorouracil; G-CSF — granulocyte colony stimulating factor
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The ACCORD 11 and MPACT studies included 
quite similar populations; however, biological inclusion 
criteria in the study with nab-paclitaxel were a little more 
rigorous. Only 8% of patients enrolled in the MPACT 
study (nominally 65 patients, half of them received 
gemcitabine alone) had a KPS of 70 (63 patients) or 
60 (2 patients), whereas the remaining 92% of patients 
had KPS score of 80–100 (which corresponds to ECOG 
PS 0–1). Although overall survival subgroup analysis 
was performed depending on performance status (HR 
0.61 for KPS 70–80; HR 0.75 for KPS 90–100), there is 
a lack of separate analysis considering the subgroup of 
patients with a KPS score of 70 [8]. Median of age of 
patients participating in both trials was 61 and 63 years, 
respectively, ranging between 25–76 and 27–88 years, 
respectively. Nearly the same results achieved in control 
groups suggest that both trials recruited patients with 
similar prognosis (Table 3).
The proportions of patients receiving second-line 
treatment were also similar: 48% in the ACCORD 
trial and 40% in the MPCT trial. In both studies the 
frequencies of second line-treatment were practically 
independent of whether either multi-drug chemotherapy 
or gemcitabine alone was used (ACCORD: 47% and 
50%, respectively; MPACT: 38 and 42%, respectively).
The data presented in the article suggest that indi-
rectly better treatment results were nominally achieved 
in the group of patients treated with FOLFIRINOX 
regimen (Table 4).
It should be underlined that, despite more frequent 
adverse events, FOLFIRINOX chemotherapy had 
Table 2. Recommendations of study authors and ASCO experts regarding management of toxicities resulting from 
chemotherapy with nab-paclitaxel and gemcitabine
Adverse events Recommendations of study authors ASCO recommendations
Haematological toxicities:
— on day 1 of cycle
— on day 8 of cycle
— on day 15 of cycle
Treatment interruption for 1 week
Omission or decrease of nab-paclitaxel and 
gemcitabine dose by 20%
Depending on complete blood count, 
omission of dose or consideration of 
treatment continuation (optionally with 
G-CSF)




Decrease nab-paclitaxel and gemcitabine 
dose by 20%
Decrease nab-paclitaxel dose by 20% and 
gemcitabine dose by 40% 
Profilaxis with G-CSF is not recommended
Neuropathy Omission and then decrease nab-paclitaxel 
dose by 20%
Decrease nab-paclitaxel dose by 20%
Nausea or vomiting Continuation with 100% of doses to 
grade 3 (inclusive); in grade 4 treatment 
discontinuation
Decrease nab-paclitaxel and gemcitabine 
dose by 20%
Others grade 3 (except nausea/vomiting):
— on day 1 of each cycle
— on the next days of cycle
Decrease nab-paclitaxel and gemcitabine 
dose by 20%
Omission of nab-paclitaxel and/or 
gemcitabine dose and then decrease nab-
paclitaxel and/or gemcitabine dose by 20%
Change dosing scheme, e.g.
— day 1 and 15 every 28 days or
— day 1 and 15 every 21 days
FN — febrile neutropenia; G-CSF — granulocyte colony stimulating factor
Table 3. Indirect comparison of results of treatment in 
control groups (gemcitabine alone) in the ACCORD 11 [7] 
and MPACT [8] studies
ACCORD 11 MPACT
mOS (months) 6.8 6.7
mPFS (months) 3.3 3.7
ORR (%) 9 7
6-month OS (%) 58 55
12-month OS (%) 21 22
18-month OS (%) 6 9
mPFS — median progression-free survival; mOS — median overall survival; 
ORR — objective response rate
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efficient in those patients as compared to gemcitabine 
alone, or whether treatment-related toxicity was more 
intense than in patients with better performance status.
Patients with relative contraindications to oxalipl-
atin, irinotecan, or infusions of fluorouracil could also 
be good candidates for such therapy. The most obvious 
example could be the patients with chronic diarrhoea or 
active, but not severe, coronary artery disease (CAD). 
Benign liver injury could also be considered as an 
indication to dose reduction or even contraindication 
to irinotecan, but according to the inclusion criteria in 
the MoH drug program it has no practical importance. 
Contrary to this, elderly patients (e.g. over 75 years of 
age) could hardly be considered as good candidates, 
due to the lack of reliable data regarding the efficacy of 
doublet or multi-drug chemotherapy in this age group.
Summary
Palliative chemotherapy in patients with pancre-
atic cancer significantly prolongs OS. For many years 
monotherapy with fluorouracil was a standard of care, 
but since 1997 chemotherapy with gemcitabine became 
a new first-line option, which enables to reach a median 
of OS slightly over 6 months. During the last 6 years the 
list of active therapeutic options included subsequent cy-
totoxic drugs, that, in multi-drug regimens, improved the 
prognosis of patients. FOLFIRINOX chemotherapy as 
well the combination of gemcitabine with nab-paclitaxel 
were compared with gemcitabine alone in phase III 
clinical trials. Taking into consideration the higher tox-
icity related to multi-drug therapy, both schemes were 
evaluated in limited populations, including patients with 
good performance status, without serious concomitant 
diseases and without significant hyperbilirubinaemia. 
Although the efficacy of FOLFIRINOX was not directly 
compared to the combination of nab-paclitaxel and 
gemcitabine, indirect comparison, partially justified by 
similar populations included to both studies, suggests 
greater benefit from triplet chemotherapy (greater mOS, 
ORR, and 6- and 12-month survival rates). Moreover, 
chemotherapy according to the FOLFIRINOX regimen 
significantly improved QoL of patients with metastatic 
pancreatic cancer. Quality of life parameters were not 
evaluated in the study with nab-paclitaxel.
In conclusion, it is quite difficult to precisely deter-
mine the place of combined chemotherapy with gem-
citabine and nab-paclitaxel in the treatment of patients 
with metastatic pancreatic cancer. Such a therapy could 
be justified in patients who closely meet the definition 
of KPS of 70; however, there are no data regarding the 
efficacy and safety of doublet chemotherapy exclusively 
in this subgroup, and for the majority of patients with 
ECOG performance status 2, monotherapy with gem-
citabine would be a safer option. 
a positive impact on patients’ QoL [7]. Quality of life 
was not analysed in the MPACT study, which gives no 
right to assume with a high degree of certainty, that 
combined therapy of nab-paclitaxel and gemcitabine 
does not deteriorate QoL. Table 5 presents an indirect 
comparison of toxicities of the chemotherapy regimens.
It is worth mentioning, that in the opinion of 
many agencies (e.g. NICE) the cost-effectiveness of 
FOLFIRINOX is better than of the combination of 
nab-paclitaxel and gemcitabine. 
Which patients have contraindications 
to FOLIRINOX chemotherapy  
but are eligible for a combination  
of nab-paclitaxel and gemcitabine?
It seems that the patients with KPS 70 could be natural 
candidates for combination chemotherapy with nab-pacli-
taxel and gemcitabine. The situation is found only in some 
patients with ECOG performance status of 2. It should 
also be emphasized that in the MPACT study this group 
of patients accounted for less than 10% of participants. It 
is not clear whether doublet chemotherapy was more 
Table 4. Indirect comparison of results of treatment in 
patients treated with multi-drug chemotherapy in the 
ACCORD 11 (FOLFIRINOX) [7] and MPACT (nab-paclitaxel 
with gemcitabine) [8] studies
ACCORD 11 MPACT
mOS (months) 11.1 8.5
mPFS (months) 6.4 5.5
ORR (%) 32 23
6-month OS (%) 76 67
12-month OS (%) 49 35
18-month OS (%) 19 16
mPFS — median progression-free survival; mOS — median overall survival; 
ORR — objective response rate
Table 5. Indirect comparison of treatment toxicities in 
patients treated with multi-drug chemotherapy in the 
ACCORD 11 (FOLFIRINOX) [7] and MPACT (nab-paclitaxel 
with gemcitabine) [8] studies
Adverse events  
grade 3 and 4





Febrile neutropenia 5 3
Thrombocytopenia 9 13
Diarrhoea 13 6
Sensitive neuropathy 9 17
Fatigue 24 17
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In patients clinically and biochemically eligible for sys-
tematic treatment based on multi-drug chemotherapy it 
seems that the FOLFIRINOX regimen is a better option, 
unless there are existing contraindications to the treat-
ment with oxaliplatin, irinotecan, and fluorouracil. Taking 
this into consideration, it is surprising and ethically diffi-
cult to accept the clinical trial designs with administration 
of nab-paclitaxel and gemcitabine in the control group 
although in patients without contraindications to FOL-
FIRINOX chemotherapy. Finally, it should be underlined 
again that appropriate management of treatment-related 
toxicities is a crucial element of the therapy of patients 
with pancreatic cancer, and quite often influences the re-
sults of therapy. Recommendations from the protocols of 
both studies could provide valuable guidance in this case. 
Especially helpful are also the suggestions of the ASCO 
experts, developed after publication of trial results and 
analyses of other publications and reports.
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